Sanofi wanted to dump Translate Bio in April, but the mRNA biotech prevailed for a $3.2B deal instead Novavax taps Sanofi, Supernus vets amid quest to get its COVID-19 vaccine over the FDA finish line Here are 3 major policy areas that health industry groups are closely watching in $3.5T infrastructure bill The 7-year itch? Boehringer culls $600M cancer pact with CureVac, heaping more woe to the biotech Recro Pharma takes manufacturing business ‘bi-coastal’ with $50M deal for CDMO Irisys Thermo Fisher’s COVID tests snare FDA green light for detecting Delta and other variants UnitedHealth, Change Healthcare enter timing agreement with DOJ over megamerger Investors are tripping on psychedelics startups despite a murky path to commercial success Hims & Hers Q2 revenue climbs 69% as company invests in more specialty care, international expansion UPDATED: Pfizer, Eli Lilly and J&J roll out COVID-19 vaccination rules as delta makes case for mandates Oscar Health expanding its footprint for the 5th straight year Featured Story | By Kyle LaHucik Sanofi was prepared to dump a quarter of its holding in Translate Bio in April—which the mRNA biotech agreed to. So how, exactly, did the French pharma end up buying Translate for $3.2 billion two weeks ago? Under-the-hood details of the deal were revealed in a Securities and Exchange Commission filing disclosed by Translate Monday. read more |
| |
|---|
|
Top Stories By Fraiser Kansteiner Novavax's new SVP of quality assurance, Nasir Egal, Ph.D., hails from Sanofi, while Jim Kelly, Novavax’s new chief financial officer and treasurer, comes from Supernus Pharmaceuticals. Novavax will channel the execs’ quality and commercial know-how toward its experimental COVID-19 vaccine, which it plans to file for a U.S. emergency nod in the fourth quarter. read more By Robert King As the Senate starts to develop the contents of a $3.5 trillion reconciliation package, industry groups are keeping a close eye on what healthcare policies could eventually be included and what could not. read more By Ben Adams Back in 2014, a German pharma and a then largely unknown fellow German biotech in CureVac penned a $600 million mRNA cancer pact. Buried in financials posted Monday morning, CureVac quietly reported that Boehringer Ingelheim has walked away from the deal, which was penned in 2014 and included $45 million upfront plus $556 million in biobucks. read more By Fraiser Kansteiner Recro has dished out nearly $50 million to acquire CDMO peer Irisys. The deal for the San Diego-based contract manufacturer jettisons Recro into the role of “full-service CDMO” with operations on both coasts, the company said. read more By Andrea Park Diagnostics developers have quickly stepped up to develop tests capable of detecting Delta and other mutations the CDC has labeled “variants of concern”—even after many projected that testing demand would peter out throughout the year with the widespread availability of COVID vaccines. read more By Paige Minemyer UnitedHealth Group and Change Healthcare have entered into a timing agreement with the Department of Justice for their planned $8 billion merger. read more By Arlene Weintraub Eighteen venture capital firms have poured more than $79 million into biopharma companies developing psychedelic compounds into therapies for depression, post-traumatic stress disorder, and more. Two IPOs in the field have outperformed expectations. But all that cash is flowing into an industry that’s facing its fair share of risks. read more By Heather Landi The COVID-19 pandemic spurred new players into the virtual care space, along with booming investments, but the increased competition is not slowing down Hims & Hers' growth. The consumer telehealth and wellness brand reported second-quarter 2021 revenue grew 69% to $61 million. read more By Fraiser Kansteiner,Noah Higgins-Dunn Johnson & Johnson and Eli Lilly are the two latest drugmakers to say they'll require vaccines for their workforce in the coming months. With COVID-19 cases expected to rise before Labor Day, the argument for vaccine mandates is growing. read more By Paige Minemyer Oscar Health said it plans to offer its individual and family plans in three new states and 146 new counties for the 2022 plan year. read more |
